Oncology Central

Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer


Colorectal cancer (CRC) continues to be one of the leading cancer types worldwide. When metastasized the disease is generally incurable and only treated with palliative intent. Metastatic CRC (mCRC) is primarily treated with 5-fluorouracil and leucovorin administrated together with either the topoisomerase inhibitor irinotecan (FOLFIRI) or with the alkylating cytostatic oxaliplatin (XELOX/FOLFOX). Although these treatment regimens have significantly improved both disease-free and overall survival, drug resistance is still a major problem, and consequently, only half of the treated mCRC patients obtain an objective response to the selected first-line treatment.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.